H.C. Wainwright analyst Mitchell Kapoor raised the firm’s price target on Lyell Immunopharma (LYEL) to $10 from $1 and keeps a Neutral rating on the shares. The firm adjusted the company’s model to account for the 20-for-1 reverse split earlier this month.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LYEL:
- Lyell Immunopharma Announces Promising CAR T-Cell Trial Data
- Lyell Immunopharma’s LYL314 shows strong response in Phase 1/2 lymphoma trial
- Lyell Immunopharma Expands Board, Appoints New Director
- Lyell Immunopharma appoints David Shook as CMO, Mark Meltz as general counsel
- Lyell Immunopharma trading resumes